Tables of Rules

INTEGRASE STRAND TRANSFER INHIBITORS

Nucleoside and Nucleotide reverse transcriptase inhibitors Protease inhibitors

Non-Nucleoside reverse transcriptase inhibitors Fusion inhibitors

HIV - 2 Integrase strand transfer inhibitors

  Mutations associated with resistance Mutations associated with "possible resistance"
RAL

T66K [10]
E92Q [1, 2]
G118R [10,17]
F121Y [10,17]
G140A/S [7]
Y143A/C/G/H/R/S [1, 3, 4, 5, 8, 14]
Q148E/G/H/K/R [1, 2]
V151L [9]
N155H/S/T [1, 2, 9]
E157Q [2]
S230R [18, 33, 34, 35]
R263K [16,18]
L74F + V75I [38]

 
EVG T66I/A/K [6]
E92Q [6]
T97A [21, 22]
G118R [17]
F121Y [9,17]
E138K
G140C/S
Y143A/C/G/H/R/S [14]
P145S [9]
S147G [21]
Q148H/R/K [6]
V151L [9]
N155H/S/T [6, 9]
E157Q [11,37]
S230R [18, 33, 34, 35]
R263K [18]
L74F + V75I [38]

DTG* 50 mg BID










50 mg QD

G118R [12,13]
F121Y [17]
V151L [9,25]
S153F/Y [9, 25,28, 36]
T66K + L74M [9]
E92Q + N155H [9, 23, 24]
Q148H/K/R + at least 2 mutations among: L74I or E138A/K/T or G140A/C/S [15]
Q148H/K/R + N155H [9,29,30]
R263K [16]


G118R [12,13]
F121Y [17]
E138A/K/T [15]
puce G140A/C/S [15]
puce Q148H/K/R [15]
puce V151L [9,25]
S153F/Y [9,25,28, 36]
puce N155H [18]
puce S230R [31]
puce R263K [16]
puce T66K + L74M [9]
puce L741 + E92Q [32]

T66K [9]
Q148H/K/R + 1 mutation among: L74I or E138A/K/T or G140A/C/S [15]









puce T66K [9]
puce E157Q [19, 20, 37]
CAB* G118R [12,13]
F121Y [17]
E138A/K/T [15]
puce G140A/C/S [15]
puce Q148H/K/R [15]
puce V151L [9,25]
S153F/Y [9,25,28, 36]
puce N155H [18]
puce S230R [31]
puce R263K [16]
puce T66K + L74M [9]
puce L741 + E92Q [32]
puce T66K [9]
puce E157Q [19, 20, 37]


RAL: raltegravir, EVG: elvitegravir, DTG: dolutegravir, CAB: cabotegravir
* Please note that rules are different for DTG 50 mg BID and 50 mg QD.
*Due to few data and to the very close structures of dolutegravir and cabotegravir rules for dolutegravir QD are transposed to cabotegravir.

For DNA provirus, impact of stop codons and G->A mutations on ARV resistance is unknown

References